This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Under $10 Set to Soar

Rosetta Genomics

Another stock in the biotechnology and drugs complex that could be poised for a sharp rebound trade is Rosetta Genomics (ROSG), which develops and commercializes diagnostic tests based on microRNAs. This stock is off to a monster start in 2012, with shares up a whopping 70%.

If you take a look at the chart for Rosetta Genomics, you'll see that this stock exploded higher back in May, when it soared from $1.40 to $23.43 a share in just a few weeks. Following that monster move, shares of ROSG started to selloff and since late June the stock has done nothing but consistently make lower highs and lower lows. That type of price behavior is bearish technical action, and it drove shares of ROSG down from $17.35 to its recent low of $4.07 a share. That move toward $4 is staring to make ROSG look interesting again from the long side, since that $4 level is a previous support zone from its run back in May. Shares of ROSG are also attractive here for an oversold bounce, since its current relative strength index reading is now 26.54.

>>Hot Biotech Stocks Traded by Hedge Funds

Traders should now look for long-biased trades in ROSG if it can manage to hold a trend above $4 a share with strong upside volume flows. I would consider any upside volume day that registers near or above 1,333,340 shares as bullish. Keep in mind that over 2.2 million shares traded on Wednesday after the stock closed up sharply. That was the first large-volume upside day we've seen for ROSG since back in June. If ROSG can hold its trend above $4 with strong upside volume flows, then this stock could easily see a massive bounce back toward $6.50 to $8 a share in the near future.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
JRCC $0.00 0.00%
DRYS $2.75 -9.24%
EXEL $4.69 8.31%
NG $6.24 3.65%
ROSG $1.22 -2.40%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs